<?xml version="1.0" encoding="UTF-8"?>
<p>Under the predominance of inactivated or attenuated vaccine technology, two formulations against polio helped to reduce polio epidemics. The Salk vaccine, composed of the inactivated virus, was used on a large scale in the USA in 1954 and in 90 countries since 1959 (
 <xref rid="B20" ref-type="bibr">20</xref>). In contrast, the oral Sabin vaccine was composed of three attenuated polioviruses and started to be used worldwide as of 1962, with high adhesion and vaccine coverage. The eradication of wild type 2 poliovirus was, in fact, announced in September 2015. However, the vaccine eventually showed serious safety issues, causing reversed virulence and paralysis in immunosuppressed individuals, and promoted outbreaks of poliovirus 2 vaccine-associated paralytic poliomyelitis (
 <xref rid="B21" ref-type="bibr">21</xref>). For these reasons, in some countries, the inactivated Salk vaccine is starting to be used again.
</p>
